


L1 1 S US 20060210624/PN
 E HISTAMINE H1 RECEPTORS/CT
 SET EXPAND CONTINUOUS
 E E3+ALL/CT
 L2 2310 S E22,E34
 E E12+ALL/CT
 L3 1468 S E45,E53
 L4 389 S L2 AND L3
 L5 0 S L2 (L) L3
 L6 94 S L4 AND (PY<=2004 OR PRY<=2004 OR AY<=2004)
 E ANTIDEPRESSANTS/CT
 E E57+ALL/CT
 L7 44667 S E82-E83,E104
 E ANTIPSYCHOTICS/CT
 E E122+ALL/CT
 L8 42195 S E147-E149,E162,E164-E165
 E MENTAL AND BEHAVIORAL DISORDERS/CT
 E E175+ALL/CT
 L9 271423 S E189-E193,E219-E284,E286
 L10 128 S L4 AND (L7 OR L8 OR L9)
 L11 35 S L10 AND (PY<=2004 OR PRY<=2004 OR AY<=2004)
 L12 59 S L6 NOT L11
 E SEDATION/CT
 E E291+ALL/CT
 L13 20599 S E303,E307,E312
 E E297/CT
 E E297+ALL/CT
 L14 11107 S E325,E326
 E BODY WEIGHT/CT
 E E329+ALL/CT
 L15 109279 S E342,E345-E349
 E COGNITION ENHANCERS/CT
 E E352+ALL/CT
 L16 65634 S E368,E376-E380
 L17 587 S L3 AND (L13 OR L14 OR L15 OR L16)
 L18 486 S L17 AND (L7 OR L8 OR L9)
 L19 116 S L18 AND (PY<=2004 OR PRY<=2004 OR AY<=2004)
 L20 96 S L19 NOT (L11 OR L12)

FILE 'REGISTRY' ENTERED AT 08:45:09 ON 05 OCT 2011
 E OLANZAPINE/CN

L21 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2011 ACS on STN
 RN 132539-06-1 REGISTRY
 ED Entered STN: 08 Mar 1991
 CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-(4-methyl-1-piperazinyl)-
 (CA INDEX NAME)
 OTHER NAMES:
 CN Integral
 CN Lanzaac
 CN LY 170053


CN Olanz
 CN Olanzapine
 CN Oleanz
 CN Olenz
 CN Olimelt
 CN Oliza
 CN Olta1
 CN ZypAdhera
 CN Zyprexa
 DR 1034315-19-9
 MF C17 H20 N4 S
 CI COM
 SR US Adopted Names Council (USAN)
 LC STN Files: ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, BIOSIS,
 BIOTECHNO,
 CA, CAPLUS, CASREACT, CBNB, CHEMCATS, CHEMLIST, CIN, CSNB, DDFU,
 DRUGU,
 EMBASE, IMSPATENTS, IMSRESEARCH, IPA, MEDLINE, MRCK*, PATDPASPC, PIRA,
 PS, RTECS*, TOXCENTER, USAN, USPAT2, USPATFULL
 (*File contains numerically searchable property data)



L21 1 S E384
 E BF2649/CN
 E BF-2649/CN
 E BF 2649/CN

L22 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2011 ACS on STN
 RN 903576-44-3 REGISTRY
 ED Entered STN: 23 Aug 2006
 CN Piperidine, 1-[3-[3-(4-chlorophenyl)propoxy]propyl]-, hydrochloride
 (1:1)
 (CA INDEX NAME)
 OTHER CA INDEX NAMES:
 CN Piperidine, 1-[3-[3-(4-chlorophenyl)propoxy]propyl]-, hydrochloride
 (9CI)
 OTHER NAMES:
 CN 1-[3-[3-(4-Chlorophenyl)propoxy]propyl]piperidine monohydrochloride
 CN BF 2.649
 CN BF 2649
 CN Ciproxidine
 MF C17 H26 Cl N O . Cl H

SR CAS Client Services
LC STN Files: CA, CAPLUS, CHEMCATS, IMSRESEARCH, TOXCENTER, USPATFULL
CRN (362665-56-3)



L22 1 S E420

FILE 'CAPLUS' ENTERED AT 08:46:10 ON 05 OCT 2011

L23 1 S L21 AND L22

L24 15 S L3 AND L21

L25 4 S L24 AND (PY<=2004 OR PRY<=2004 OR AY<=2004)

L25 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2011 ACS on STN

AB Histamine H3 inverse agonists or histamine H3 antagonists are useful, alone or in combination with a neuroleptic agent, for treating or preventing movement disorders, including tremor, such as essential tremor, and tremor associated with Parkinson's disease, cranofacial trauma, multiple sclerosis, stroke, dystonia, and neuropathic, toxic or drug-induced tremor. Preparation and activity of 2-(1-cyclopentylpiperidin-4-yloxy)-5-(4-cyanophenyl)pyrimidine is included.

ACCESSION NUMBER: 2005:1123759 CAPLUS Full-text

DOCUMENT NUMBER: 143:379851

TITLE: Treatment of tremor or other movement disorder with histamine H3 inverse agonists or histamine H3 antagonists

INVENTOR(S): Marino, Michael J.; Seabrook, Guy R.

PATENT ASSIGNEE(S): Merck & Co., Inc., USA

SOURCE: PCT Int. Appl., 17 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
WO 2005097111	A2	20051020	WO 2005-US9562	20050322

<--

WO 2005097111 A3 20060427

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM,

ZW

RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,

AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

EP 1732544 A2 20061220 EP 2005-732633 20050322
 <--
 R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR
 US 20080242657 A1 20081002 US 2006-593933 20060921
 <--
 PRIORITY APPLN. INFO.: US 2004-556803P P 20040326
 <--
 US 2004-561188P P 20040409
 <--
 US 2004-629099P P 20041118
 <--
 WO 2005-US9562 W 20050322

L25 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2011 ACS on STN

AB The invention relates to a drug formulation with an antipsychotic or an antidepressant, which causes adverse effects like body weight gain or sedation when administered, and an histamine H3 receptor antagonist or inverse agonist. The histamine H3 receptor antagonist or inverse agonist should be present in the formulation in therapeutically effective quantities to ensure at least one of the three following effects on the adverse effects induced by the antipsychotic or the antidepressant: suppression or limitation of weight gain, suppression or limitation of the decrease in vigilance, enhancement of the pro-cognitive effect of the treatment.

ACCESSION NUMBER: 2005:589 CAPLUS Full-text

DOCUMENT NUMBER: 142:79960

TITLE: New psychiatric drug formulation with an antipsychotic

or antidepressant and an histamine H3 receptor antagonist for the prevention of psychotropic adverse effects

INVENTOR(S): Schwartz, Jean Charles; Rousseau Lecomte, Jeanne Marie

PATENT ASSIGNEE(S): Bioprojet, Fr.
 SOURCE: Fr. Demande, 32 pp.

CODEN: FRXXBL

DOCUMENT TYPE: Patent

LANGUAGE: French

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
FR 2856596	A1	20041231	FR 2003-7836	20030627
<--				
FR 2856596	B1	20070427		
CA 2530381	A1	20050106	CA 2004-2530381	20040625
<--				
WO 2005000315	A1	20050106	WO 2004-FR1628	20040625
<--				

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,
SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,
SN, TD, TG

EP 1641461 A1 20060405 EP 2004-767475 20040625
<--
EP 1641461 B1 20100929
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK
JP 2007516160 T 20070621 JP 2006-516331 20040625
<--
PT 1641461 E 20101013 PT 2004-767475 20040625
<--
AT 482711 T 20101015 AT 2004-767475 20040625
<--
ES 2350103 T3 20110118 ES 2004-767475 20040625
<--
MX 2005013877 A 20060313 MX 2005-13877 20051216
<--
US 20060210624 A1 20060921 US 2005-562396 20051227
<--
PRIORITY APPLN. INFO.: FR 2003-7836 A 20030627
<--
WO 2004-FR1628 W 20040625
<--

L26 0 S L2 AND L22